Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia.

Stiles, C E, Steeds, R P and Drake, W M (2020) Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia. Annales d'endocrinologie. ISSN 2213-3941.

Full text not available from this repository.
Official URL:


The surveillance strategy for patients taking low dose cabergoline for hyperprolactinaemia is controversial. As more evidence has emerged that the risks of cardiac valvulopathy in this population of patients are low, fewer and fewer endocrinologists adhere strictly to the original medicines and healthcare products agency MHRA guidance of "at least" annual echocardiography. Strict adherence to this guidance would be costly in monetary terms (£5.76 million/year in the UK) and also in resource use (90,000 extra echocardiograms/year). This article reviews the proposed pathophysiological mechanism underlying the phenomenon of dopamine agonist valvulopathy, the characteristic echocardiographic changes seen, summarises the published literature on the incidence of valvulopathy with low dose cabergoline and examines the previous and current evidence-based screening guidelines.

Item Type: Article
Subjects: WK Endocrine system. Endocrinology
Divisions: Ambulatory Care > Endocrinology
Related URLs:
Depositing User: Mr Philip O'Reilly
Date Deposited: 20 Mar 2020 15:30
Last Modified: 20 Mar 2020 15:30

Actions (login required)

View Item View Item